New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.» Read More
LONDON, Jan 24- GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza from Novo Nordisk, as well as Byetta and Bydureon from Bristol-Myers Squibb and AstraZeneca.
Jan 24- Bristol-Myers Squibb Co's quarterly sales and earnings beat Wall Street expectations, helped by cost cuts and growing sales of its treatments for cancer, blood clots and diabetes. The company on Friday said it earned $726 million, or 44 cents per share, in the fourth quarter.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
With uncertainty rampant in the market, pros will be watching earnings very closely. Which results matter most to Cramer?
Jan 15- Merck& Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not bound to follow the advice of its advisory panels but typically does so.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
WASHINGTON, Jan 14- The U.S. Food and Drug Administration appears skeptical that data submitted by Johnson& Johnson proves its anticoagulant Xarelto is effective in reducing the risk of further heart problems in patients who have recently suffered a heart attack.
*Shares in AstraZeneca rise 2 percent. LONDON, Jan 14- AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries, with 2017 revenue likely to be broadly in line with the 2013 level.
Jan 13- Lexicon Pharmaceuticals Inc said its chief executive would leave and it would cut its workforce by about 45 percent, as it moves its focus away from drug discovery to completing the studies of its drugs in late-stage development. The company said Arthur Sands, CEO since 1995 and a co-founder, intends to develop a succession plan with the board.
The "Fast Money" traders share their final trades of the day.
Jan 8- U.S. health regulators on Wednesday approved an AstraZeneca drug from a new class of medicines to treat type 2 diabetes after previously rejecting it over safety concerns. The medicine was co-developed by Bristol-Myers Squibb Co and AstraZeneca.
Some of Wednesday's midday movers:
Dec 23- The U.S. Food and Drug Administration said on Monday it has approved Novo Nordisk's drug Tretten to prevent bleeding in patients with a rare blood clotting disorder. Patients with congenital Factor XIIIA-subunit deficiency do not make enough of the Factor XIII protein that is important for normal blood clotting, the FDA said.
Companies are making headlines before the bell Thursday.
AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture in a deal worth $4.1 billion.
LONDON, Dec 19- AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture for up to $4.1 billion in a deal that will help return the group to growth, sending its shares to an new high.
Cubist Pharmaceuticals is focused on treatments for fighting superbugs, an area many drug developers are avoiding. But its success may attract their attention.
LONDON, Dec 16- A new battle is looming over access to antiviral medicines in developing countries- this time for treating hepatitis C- more than a decade after a global showdown over the price of AIDS drugs in Africa.
Some of Friday's midday movers:
*AstraZeneca shares gain 2.2 percent. Dec 13- A new type of diabetes drug from Bristol-Myers Squibb and AstraZeneca has been endorsed by U.S. medical experts, two years after it was rejected by regulators because of safety concerns.